- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06097364
Uno studio per scoprire come funziona odronextamab combinato con la chemioterapia e quanto è sicuro rispetto a rituximab e chemioterapia in partecipanti adulti con linfoma follicolare non trattato in precedenza (OLYMPIA-2)
Uno studio randomizzato di fase 3, in aperto, per confrontare l'efficacia e la sicurezza di odronextamab (REGN1979), un anticorpo bispecifico anti-CD20x anti-CD3, combinato con chemioterapia rispetto a rituximab combinato con chemioterapia in partecipanti precedentemente non trattati affetti da linfoma follicolare (OLYMPIA- 2)
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory") are eligible to take part only in Part 1A of the study.
This study is made up of 3 parts: Part 1A (non-randomized), Part 1B and Part 2 (randomized - controlled).
The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy to be used in Part 2 of the study.
The aim of Part 2 of the study is to assess how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy (the current standard-of-care for NHL). Standard-of-care means the usual medication expected and used when receiving treatment for a condition.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
- The impact from the study drug on quality-of-life and ability to complete routine daily activities
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital
-
Waratah, New South Wales, Australia, 2298
- Calvary Mater Newcastle
-
-
Queensland
-
Benowa, Queensland, Australia, 4217
- Pindara Private Hospital
-
-
-
-
-
Vienna, Austria, 1090
- Universitatsklinik fur Kinder und Jungendheilkunde
-
Wels, Austria, 4600
- Klinikum Wels-Grieskirchen
-
-
Lower Austria
-
Sankt Pölten, Lower Austria, Austria, 3100
- Karl Landsteiner University Hospital St. Poelten
-
-
Styria
-
Graz, Styria, Austria, 8036
- Medical University of Graz
-
Leoben, Styria, Austria, 8700
- Landeskrankenhaus Hochsteiermark
-
-
Tyrol
-
Innsbruck, Tyrol, Austria, 6020
- Innsbruck Medical University
-
-
Upper Austria
-
Linz, Upper Austria, Austria, 4020
- Kepler University Hospital
-
-
-
-
-
Brussels, Belgio, 1000
- Institut Jules Bordet
-
Liège, Belgio, 4000
- Centre Hospitalier Regional de la Citadelle
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgio, 9000
- Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
-
Sint-Niklaas, Oost-Vlaanderen, Belgio, 9100
- Verenigde Ziekenhuizen van Waas en Durme
-
-
West-Vlaanderen
-
Bruges, West-Vlaanderen, Belgio, 8000
- Algemeen Ziekenhuis St Jan Brugge Oostende Av
-
Kortrijk, West-Vlaanderen, Belgio, 8500
- AZ Groeninge
-
-
-
-
-
Rio de Janeiro, Brasile, 20231050
- Instituto Nacional de Cancer Jose Alencar Gomes da Silva
-
São Paulo, Brasile, 01323-903
- Hospital Alemao Oswaldo Cruz
-
São Paulo, Brasile, 08270-070
- Casa de Saude Santa Marcelina
-
São Paulo, Brasile, 01509-010
- AC Camargo Cancer Center
-
São Paulo, Brasile, 05403-000
- Clinical Hospital of Medicine School at Sao Paulo University
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasile, 41253-900
- Hospital Sao Rafael
-
Salvador, Estado de Bahia, Brasile, 41950-640
- Ensino e Terapia de Inovacao Clinica Amo (Etica)
-
Salvador, Estado de Bahia, Brasile, 40050-410
- Hospital Santa Izabel - Santa Casa de Misericordia da Bahia
-
-
Federal District
-
Brasília, Federal District, Brasile, 70200-730
- Hospital Sirio Libanes Brasilia
-
Brasília, Federal District, Brasile, 70390-140
- Instituto DOr de Pesquisa e Ensino Df Star
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasile, 30380-472
- Instituto Mario Pena de Ensino Pesquisa e Inovacao
-
Uberlândia, Minas Gerais, Brasile, 38408-008
- Centro Oncologico do Triangulo (COT) - Uberlandia
-
-
Paraná
-
Curitiba, Paraná, Brasile, 81520-060
- Hospital Erasto Gaertner
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brasile, 59062-000
- Liga Norte Riograndense Contra o Cancer
-
-
Rio Grande do Sul
-
Bento Gonçalves, Rio Grande do Sul, Brasile, 95700-084
- Instituto Tacchini de Pesquisa em Saude
-
Passo Fundo, Rio Grande do Sul, Brasile, 99010-080
- Instituto do Cancer em Hospital Sao Vicente de Paulo
-
Porto Alegre, Rio Grande do Sul, Brasile, 90035-903
- Hospital de Clinicas de Porto Alegre
-
-
Santa Catarina
-
Joinville, Santa Catarina, Brasile, 89201-260
- Centro de Hematologia e Oncologia
-
Lages, Santa Catarina, Brasile, 88501-001
- Animi Unidade de Tratamento Oncologico Ltda
-
-
São Paulo
-
Barretos, São Paulo, Brasile, 14784-400
- Fundacao Pio XII Hospital de Amor
-
Jaú, São Paulo, Brasile, 17210-080
- Amaral Carvalho Hospital
-
Ribeirão Preto, São Paulo, Brasile, 14048-900
- Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
-
-
-
-
North Central Czech Republic
-
Hradec Králové, North Central Czech Republic, Cechia, 50005
- University Hospital Hradec Kralove
-
-
South Moravian
-
Brno, South Moravian, Cechia, 62500
- University Hospital Brno
-
-
-
-
Las Condes
-
Santiago, Las Condes, Chile, 7620157
- Hospital Clinico Universidad de Los Andes
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 7560907
- Centro Oncologia de Precision Universidad Mayor
-
Santiago, Santiago Metropolitan, Chile, 7580206
- Inmunocel
-
Santiago, Santiago Metropolitan, Chile, 7550000
- Pontificia Universidad Catolica de Chile
-
-
-
-
-
Grenoble, Francia, 38043
- Centre Hospitalier Universitaire de Grenoble
-
Le Puy-en-Velay, Francia, 43012
- Centre Hospitalier Emile Roux
-
Lens, Francia, 62300
- Centre Hospitalier de Lens (Centre Hospitalier Dr Schaffner dLens)
-
Paris, Francia, 75010
- Hopital Saint Louis
-
Pessac, Francia, 33600
- Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Sud - Hôpital Haut Lévêque
-
Saint-Etienne, Francia, 42055
- CHU de Saint-Etienne
-
Saint-Nazaire, Francia, 44600
- Centre Hospitalier de Saint Nazaire
-
-
Alpes Maritimes
-
Cannes, Alpes Maritimes, Francia, 06400
- Cannes Hospital (Centre Hospitalier Cannes Simone Veil)
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, Francia, 37044
- CHRU de Tours
-
-
Gard
-
Nîmes, Gard, Francia, 30029
- Institut de Cancerologie du Gard
-
-
New Aquitaine
-
Mont-de-Marsan, New Aquitaine, Francia, 40024
- Centre Hospitalier de Mont-de-Marsan
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, Francia, 44093
- Nantes University Hospital
-
-
Pontoise
-
Cergy-Pontoise, Pontoise, Francia, 95300
- The Novo Hospital North West Val Deoise
-
-
Île-de-France Region
-
Argenteuil, Île-de-France Region, Francia, 95100
- Hopital Victor Dupouy Argenteuil
-
-
-
-
-
Kiel, Germania, 24116
- Stadtisches Krankenhaus Kiel
-
Neuss, Germania, 41462
- MVZ fuer Haematologie und Onkologie Rhein-Kreis GmbH
-
-
-
-
-
Beersheba, Israele, 84101
- Soroka University Medical Center
-
Haifa, Israele, 3109601
- Rambam Health Care Campus
-
Jerusalem, Israele, 91200
- Hadassah Medical Center
-
Petah Tikva, Israele, 49100
- Rabin Medical Center
-
Tel Aviv, Israele, 64239
- The Tel Aviv Sourasky Medical Center
-
Tel Aviv, Israele, 6971028
- Assuta Medical Centers
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israele, 9103102
- Shaare Zedek Medical Center
-
-
-
-
-
Milan, Italia, 20141
- Istituto Europeo di Oncologia
-
Milan, Italia, 20162
- ASST Grande Ospedale Metropolitano Niguarda - Main Address
-
Milan, Italia, 20122
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Modena, Italia, 41124
- A.O.U. di Modena
-
Naples, Italia, 80131
- Federico II University
-
Perugia, Italia, 06132
- Azienda Ospedaliera di Perugia
-
Pisa, Italia, 56126
- University of Pisa, Section of Hematology
-
Potenza, Italia, 85100
- Azienda Ospedaliera Regionale San Carlo
-
Ravenna, Italia, 48121
- UO Ematologia Ravenna
-
Reggio Emilia, Italia, 42123
- Azienda Unita Sanitaria Locale Irccs Arcispedale Santa Maria Nuova
-
Rome, Italia, 00161
- Azienda Osperdaliero-Universitaria Policlinico Umberto 1
-
Udine, Italia, 33100
- Azienda Sanitaria Universitaria del Friuli Centrale
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, Italia, 47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
-
Piedmont
-
Turin, Piedmont, Italia, 10137
- Azienda Ospedaliera Ordine Mauriziano Torino, Presidio Umberto I of Turin
-
-
Sicily
-
Palermo, Sicily, Italia, 90127
- Azienda Ospedaliera Universitario Policlinico Palermo
-
-
-
-
-
Bydgoszcz, Polonia, 85-168
- Szpital Uniwersytecki Nr2 Bydgoszcz
-
Gdansk, Polonia, 80-952
- Uniwersyteckie Centrum Kliniczne, Building of the Non-Invasive Medicine Center
-
Katowice, Polonia, 40-519
- Pratia Onkologia Katowice
-
Lodz, Polonia, 93-513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital)
-
Lublin, Polonia, 20-954
- Centrum Innowacyjnych Terapii Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
-
Warsaw, Polonia, 02781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa
-
Wałbrzych, Polonia, 58-300
- Szpital Szpecjalistyczny w Walbrzychu
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polonia, 30-510
- Matopolskie Centrum Medyczne S.C.
-
-
Wielkopolska
-
Skorzewo, Wielkopolska, Polonia, 60185
- Aidport Sp. z o.o.
-
-
-
-
-
Aberdeen, Regno Unito, AB25 2ZN
- NHS Grampian: Aberdeen Royal Infirmary
-
-
Cornwall
-
Truro, Cornwall, Regno Unito, TR1 3LJ
- Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital
-
-
London
-
Uxbridge, London, Regno Unito, UB8 3NN
- The Hillingdon Hospitals NHS Foundation Trust
-
-
West Midlands
-
Birmingham, West Midlands, Regno Unito, B15 2SY
- University Hospitals Birmingham NHS Foundation Trust
-
-
-
-
-
Lugo, Spagna, 27003
- Hospital Universitario Lucus Augusti
-
Madrid, Spagna, 28027
- Clinica Universidad de Navarra - Madrid
-
Madrid, Spagna, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Spagna, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spagna, 28031
- Hospital Universitario Infanta Leonor
-
Madrid, Spagna, 28040
- Hospital Universitario Fundacion Jimenez Diaz
-
Ourense, Spagna, 32005
- Complexo Hospitalario Universitario de Ourense
-
Pamplona, Spagna, 31008
- Clinica Universidad de Navarra- Pamplona
-
Salamanca, Spagna, 37007
- Hospital Universitario de Salamanca
-
Seville, Spagna, 41009
- Hospital Universitario Virgen Macarena
-
Valencia, Spagna, 46009
- Instituto Valenciano de Oncologia
-
Valencia, Spagna, 46010
- Hospital Clinico Universitario de Valencia
-
-
Andalusia
-
Seville, Andalusia, Spagna, 41013
- Hospital Universitario Virgen del Rocio
-
-
Barcelona
-
Sabadell, Barcelona, Spagna, 08208
- Parc Tauli Sabadell Hospital Universitari
-
Terrassa, Barcelona, Spagna, 08221
- Hospital Universitari Mutua Terrassa
-
-
Bizkaia
-
Barakaldo, Bizkaia, Spagna, 48903
- Cruces University Hospital (Hospital Universitario Cruces)
-
-
Madrid
-
Majadahonda, Madrid, Spagna, 28222
- Hospital Universitario Puerta de Hierro - Majadahonda
-
Pozuelo de Alarcón, Madrid, Spagna, 28223
- Hospital Universitario Quiron Salud Madrid
-
-
Navarre
-
Pamplona, Navarre, Spagna, 31008
- Hospital Universitario de Navarra
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Spagna, 33011
- Hospital Universitario Central de Asturias
-
-
Valencia
-
Alicante, Valencia, Spagna, 03010
- Hospital General Universitario Doctor Balmis Alicante
-
-
-
-
Florida
-
Plantation, Florida, Stati Uniti, 33322
- Boca Raton Clinical Research (BRCR) Global
-
-
Indiana
-
Noblesville, Indiana, Stati Uniti, 46062
- Investigative Clinical Research of Indiana
-
-
Kansas
-
Wichita, Kansas, Stati Uniti, 67214
- Cancer Center of Kansas
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- University of Kentucky
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Henry Ford Health System
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Cancer and Hematology Centers of Western Michigan
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Center for Oncology and Blood Disorders
-
-
Utah
-
Ogden, Utah, Stati Uniti, 84405
- Community Cancer Trials of Utah
-
-
Wisconsin
-
Waukesha, Wisconsin, Stati Uniti, 53188
- Prohealth Care Inc
-
-
-
-
-
Khon Kaen, Tailandia, 40002
- Khon Kaen University
-
-
Krung Thep Maha Nakhon [Bangko]
-
Bangkok, Krung Thep Maha Nakhon [Bangko], Tailandia, 10330
- Chulalongkorn University
-
-
-
-
-
Kaohsiung City, Taiwan, 83301
- Kaohsiung Chang Gung Memorial Hospital
-
Kaohsiung City, Taiwan, 80756
- Kaohsiung Medical University Hospital
-
New Taipei City, Taiwan, 23561
- Taipei Medical University - Shuang Ho Hospital
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 11490
- Tri-Service General Hospital
-
Taipei, Taiwan, 11696
- Taipei Medical University Multipal Wan Fang University
-
-
-
-
-
Ankara, Turchia (Türkiye), 06100
- Liv Hospital Ankara
-
Istanbul, Turchia (Türkiye), 34365
- VKV American Hopital
-
Istanbul, Turchia (Türkiye), 34418
- Istanbul University
-
Kayseri, Turchia (Türkiye), 38039
- Erci̇yes Uni̇versi̇ty
-
Samsun, Turchia (Türkiye), 55270
- Ondokuz Mayıs University
-
Zonguldak, Turchia (Türkiye), 67100
- Zonguldak Bulent Ecevit University
-
-
Ankara
-
Mamak, Ankara, Turchia (Türkiye), 06620
- Ankara University Faculty of Medicine
-
Yenimahalle, Ankara, Turchia (Türkiye), 06200
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
-
Central Anatolia
-
Ankara, Central Anatolia, Turchia (Türkiye), 06100
- Gazi University
-
-
Mersin
-
Mezitli, Mersin, Turchia (Türkiye), 33200
- VM Medical Park Mersin Hospital
-
-
Serdivan
-
Sakarya, Serdivan, Turchia (Türkiye), 54050
- Sakarya University
-
-
Suleymanpasa
-
Tekirdağ, Suleymanpasa, Turchia (Türkiye), 59100
- Tekirdag Namik Kemal University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
-
Have diagnosis of cluster of differentiation 20 positive (CD20+) FL grade 1-3a, stage II bulky or stage III / IV
- For Part 1A: previously untreated participants who have Follicular Lymphoma International Prognostic Index (FLIPI)-1 score of 3 to 5, or R/R FL
- For Part 1B: previously untreated participants who have FLIPI-1 score of 3 to 5
- For Part 2: previously untreated participants who have FLIPI-1 score of 0 to 5
-
Have measurable disease on cross sectional imaging documented by diagnostic computed tomography [CT], or magnetic resonance imaging [MRI] imaging, as described in the protocol
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
-
Adequate bone marrow and hepatic function.
Key Exclusion Criteria:
- Participants with central nervous system lymphoma or leptomeningeal lymphoma
- Participants with histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma
- Participants with Waldenström macroglobulinemia (WM, lymphoplasmacytic lymphoma), grade 3b follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma
- Recent major surgery and history or organ transplantation
- A malignancy other than NHL unless the participant is adequately and definitively treated and any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Odronextamab + Chemotherapy
Part 1 of the study includes ordonextamab dose escalation for participants with previously untreated FL and relapsed/refractory FL (Part 1A only) followed by a randomized exploration of 2 regimens of odronextamab (Odro) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) with the objective of dose optimization (Part 1B) in previously untreated patients with FL. |
Administered by intravenous (IV) infusion
Altri nomi:
Administered by IV infusion
Altri nomi:
Administered by IV infusion
Altri nomi:
Administered orally (PO)
Altri nomi:
|
|
Comparatore attivo: Rituximab + Chemotherapy
In Part 2 only, participants will be randomized 1:1:1 to receive rituximab (R) with chemotherapy (CHOP), followed by rituximab monotherapy maintenance. |
Administered by intravenous (IV) infusion
Altri nomi:
Administered by IV infusion
Altri nomi:
Administered by IV infusion
Altri nomi:
Administered orally (PO)
Altri nomi:
Administered by IV infusion, or subcutaneous (SC)
Altri nomi:
Administered by IV infusion
Altri nomi:
|
|
Sperimentale: Odronextamab + Chemotherapy + Maintenance
In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy [CHOP, or cyclophosphamide, vincristine, and prednisone (CVP)], followed by odronextamab monotherapy maintenance. |
Administered by intravenous (IV) infusion
Altri nomi:
Administered by IV infusion
Altri nomi:
|
|
Sperimentale: Odronextamab + Chemotherapy + No maintenance
In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy (CHOP, or CVP) without maintenance. |
Administered by intravenous (IV) infusion
Altri nomi:
Administered by IV infusion
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapy
Lasso di tempo: Up to 35 days
|
Part 1, DLT period |
Up to 35 days
|
|
Incidence of treatment-emergent adverse events (TEAEs) of odronextamab in combination with chemotherapy
Lasso di tempo: Up to 2 years
|
Part 1, Treatment period |
Up to 2 years
|
|
Severity of TEAEs of odronextamab in combination with chemotherapy
Lasso di tempo: Up to 2 years
|
Part 1, Treatment period |
Up to 2 years
|
|
Complete Response rate at 30 months (CR30) assessed by independent central review (ICR)
Lasso di tempo: Up to 30 months
|
Part 2 |
Up to 30 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS)
Lasso di tempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
CR30 as assessed by local investigator
Lasso di tempo: Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Incidence of TEAEs
Lasso di tempo: Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Severity of TEAEs
Lasso di tempo: Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Change in Patient Global Impression of Severity (PGIS)
Lasso di tempo: Up to 5 years
|
Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe). |
Up to 5 years
|
|
Change in Patient Global Impression of Change (PGIC)
Lasso di tempo: Up to 5 years
|
Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse. |
Up to 5 years
|
|
BOR as assessed by ICR
Lasso di tempo: Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Odronextamab concentrations in serum when administered with chemotherapy
Lasso di tempo: Up to 30 months
|
Part 1, Maintenance period and Part 2, Induction period |
Up to 30 months
|
|
Odronextamab concentrations in serum when administered as monotherapy
Lasso di tempo: Up to 30 months
|
Part 1 and Part 2, Maintenance period |
Up to 30 months
|
|
Incidence of anti-odronextamab antibodies (ADAs)
Lasso di tempo: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Titers of ADAs to odronextamab
Lasso di tempo: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Incidence of neutralizing antibodies (NAb) to odronextamab
Lasso di tempo: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Best overall response (BOR) as assessed by the investigator
Lasso di tempo: Up to 30 months
|
Part 1, end of Induction period and end of Maintenance period |
Up to 30 months
|
|
Progression free survival (PFS) as assessed by ICR
Lasso di tempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Change in patient reported physical functioning scale scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cancer-30 (EORTC-QLQ-C30)
Lasso di tempo: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
PFS as assessed by local investigator
Lasso di tempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Event-free survival (EFS) as assessed by ICR
Lasso di tempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
EFS as assessed by local investigator
Lasso di tempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
BOR as assessed by local investigator
Lasso di tempo: Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Duration of response (DOR) assessed by ICR
Lasso di tempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
DOR as assessed by local investigator
Lasso di tempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Time to next anti-lymphoma treatment (TTNT)
Lasso di tempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Change in patient reported health related quality of life (HRQoL) as measured by EORTC-QLQ-C30
Lasso di tempo: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in cancer disease as measured by EORTC-QLQ-C30
Lasso di tempo: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in treatment related symptoms as measured by EORTC-QLQ-C30
Lasso di tempo: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in patient-reported lymphoma disease as measured by the Lymphoma Subscale of the Functional Assessment of Cancer Treatment-Lymphoma (FACT-LymS)
Lasso di tempo: Up to 5 years
|
Part 2 The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Up to 5 years
|
|
Change in treatment-related symptoms as measured by the FACT-LymS
Lasso di tempo: Up to 5 years
|
Part 2 The FACT-LymS includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Up to 5 years
|
|
Change in patient-reported general health status per EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
Lasso di tempo: Up to 5 years
|
Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state". |
Up to 5 years
|
|
Change in patient-reported treatment side effects burden per Functional Assessment of Cancer Therapy-General Global Population Item 5 (FACT-G GP5)
Lasso di tempo: Up to 5 years
|
Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Up to 5 years
|
|
Change in score of the FACT-G GP5 item in the patient population
Lasso di tempo: Up to 5 years
|
Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Up to 5 years
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Clinical Trial Management, Regeneron Pharmaceuticals
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Neoplasie
- Attributi della malattia
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Linfoma
- Condizioni patologiche, segni e sintomi
- Malattie emiche e linfatiche
- Ricorrenza
- Linfoma, follicolare
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Idrocarburi
- Idrocarburi, ciclici
- Carboidrati
- Alcaloidi
- Idrocarburi policiclici aromatici
- Idrocarburi, aromatici
- Composti policiclici
- Glicosidi
- Indoli
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Senape di fosforamide
- Composti di senape di azoto
- Composti di senape
- Idrocarburi, alogenati
- Fosforamidi
- Composti organofosfori
- Incintadienetrioli
- Incintadienediols
- Vinca Alkaloids
- Alcaloidi di triptamina di secologia
- Alcaloidi indolo
- Indolizidine
- Indolizine
- Antracicline
- Naftaceni
- Aminoglicosidi
- Anticorpi, monoclonali, derivati da murina
- Daunorubicina
- Prednisolone
- Rituximab
- Prednisone
- Ciclofosfamide
- Doxorubicina
- Vincristina
- Metilprednisolone
Altri numeri di identificazione dello studio
- R1979-ONC-2075
- 2022-502113-28-00 (Altro identificatore: EUCT Number)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Periodo di condivisione IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Criteri di accesso alla condivisione IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- CODICE_ANALITICO
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .